Novel 4-azasteroid, type 1 of 5-alpha reductase selective inhibitor with steroid structure - azasteroid. Not an antiandrogen.
Mechanism:
MK386, reversibly inhibit type 1 of 5 alpha-reductase in competitive mode, resulting in suppression of serum DHT.
Clinical studies indicate, that MK386 alone reduce DHT level only by 20-30%. But incombination with finastiride (type 2 5-alfa-reductase inhibitor) DHT level is reduceed by an average of 89% (compare: Finasteride alone reduce DHT level by 68%).
No studies on the model of human androgenetic alopecia is known.
In the future, it can be used topically for treatment of androgenetic alopecia. |
|
|
|
